Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Why the weakness today?

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Apr 09, 2021 7:47pm

187 Views

Post# 32971634

RE:RE:Why the weakness today?

TheBearInTheWoods wrote: If these guy had anything they wouldn't be changing an endpoint after a trial nor would they be pivoting to DMT. Smart money will use this retail pump to exit.

This was at .35 btw, but I was called a basher .... have a great weekend

<< Previous

Bullboard Posts

Next >>

Consumer advocacy law firm investigates Microsoft over X-Box data concerns